HLS Therapeutics to Commercialize Cholesterol-Lowering Drugs Nexletol and Nexlizet in Canada Under Esperion Therapeutics Agreement

HLS Therapeutics will commercialize two cholesterol-lowering medications, Nexletol and Nexlizet, in Canada, following an agreement with Esperion Therapeutics. The agreement grants HLS Therapeutics the rights to distribute and market the drugs within the Canadian market. Under the terms of the agreement, HLS Therapeutics gains commercial rights to Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe). These medications are oral, once-daily drugs designed to lower LDL-cholesterol. Esperion Therapeutics developed and manufactures the drugs. The partnership enables HLS Therapeutics to expand its portfolio in the cardiovascular therapeutic area.

Newsflash | Powered by GeneOnline AI
Date: May 9, 2025

Related posts:

Protein AP2A1 Linked to Reversing Cellular Aging Former NIH Director Francis Collins Announces Retirement, Advocates for Respect Towards Agency Staff Data Clean Rooms Revolutionize Secure Healthcare Data Sharing Study Finds Timing of Prenatal Stress Influences Infant Stress Responses by Gender

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後